恩替卡韦抗乙肝病毒的临床应用

宋波; 陈焕永; 邵凤娟

恩替卡韦抗乙肝病毒的临床应用

哈尔滨医科大学第一临床医学院感染三科

基金项目:

黑龙江省青年科学技术专项基金(QC07C70)；黑龙江省教育厅科学技术研究项目基金(11511214)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 3228
- HTML全文浏览量: 1
- PDF下载量: 990
- 被引次数: 0
出版历程
- 出版日期: 2009-04-20

Research funding:

摘要

HTML全文

参考文献(24)

[1]Peters MG, Hann H, Martin P, et al.Adefovir dipivoxil alone or incombination with lamivudine in patients with lamivudine-resistantchronic hepatitis B[J].Gastroenterology, 2004, 16∶91-101.

[2]Levine S, Hernandez D, Yamanaka G, et a1.Efficacies of entecaviragainst lamivudine-resistant hepatitis B virus replication and recom-binant polymerases in vitro[J].Antimicrob Agents Chemother, 2002, 46 (8) ∶2525—2532.

[3]Buti M, Esteban R.Entecavir, FTC, L-FMAU, LdTand others[J].Hepatol, 2003, 39 (supp1) ∶S139-S142.

[4]Yamanaka G, Wilson T, Innaimo S, et al.Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis Bvirus[J].Antimicrob Agents Chemother, 1999, 43 (1) ∶190-193.

[5]Perrillo RP.Current treatment of chronic hepatitis B:benefits andlimitations[J].Semin Liver Dis, 2005, 25 (Suppl 1) ∶20-28.

[6]U.S.Food and Drug Administration.Drug Approval Package Ente-cavir.July 12, 2005.Available[DB/OL].http://www.fda.gov/cder/foi/nda/2005/21797 Baraclude TOC.htm.

[7]De Man RA, Wolters LM, Nevens F, et a1.Safety and efficacy of o-ral entecavir given for28 days in patients with chronic hepatitis B vi-rus infection[J].Hepatology, 2001, 34 (3) ∶578-582.

[8]Wolters LM, Hansen BE, Niesters HG, et a1.Viral dynamics duringand after entecavir therapy in patients with chronic hepatitis B[J].JHepatol, 2002, 37 (1) ∶137—144.

[9]Colonno RJ, Genovesi EV, Medina I, et al.Long-term entecavirtreatment results in sustained antiviral efficacy and prolonged lifespan in the woodchuck model of chronic hepatitis infection[J].J In-fect Dis, 2001, 184 (10) ∶1236-1245.

[10]Marion PL, Salazar FH, Winters MA, et al.Potent efficacy of ente-cavir (BMS-200475) in a duck model of hepatitis B virus replica-tion[J].Antimicrob Agents Chemother, 2002, 46 (1) ∶82-88.

[11]Ulander JG, Colonno RJ, Sidwell RW, et al.Characterization ofantiviral activity of entecavir in transgenic mice expressing hepatitis Bvirus[J].Antiviral Res, 2003, 59 (3) ∶155-161.

[12]Gish RG, Lok AS, Chang TT, et al.Entecavir is superior to lamivu-dine for the treatment of HBeAg (+) chronic hepatitis B:results ofphaseⅢstudy ETV-022 in nucleoside-naive patients[J].Hepa-tology, 2004, 40 (4 Suppl 1) ∶193A.

[13]Chang TT, Chao YC, Sollano J, et al.Entecavir (ETV) treatmentthrough 96 weeks results in substantial virologic and biochemical im-provement and HBeAg seroconversion in HBeAg (+) chronic hepati-tis B (CHB) patients (study ETV-022) [J].Gastroenterol Hepa-tol, 2006, 21 (supp1 2) ∶Abstract 52.

[14]Chang TT, Gish RG, de Man, et al.Acomparison of entecavir andlamivudine for HBeAg-positive chronic hepatitis B[J].N Engl JMed, 2006, 354 (10) ∶1001-1010.

[15]Han S, Chang T, Chao Y.Four-Year Entecavir Treatment in Nu-cleoside-Naive HBeAg (+) Patients:Results from Studies ETV-022 and-901 58th Annual Meeting of the American Association forthe Study of Liver Diseases[Z].Boston, MA, November26, 2007, Abstract 938.

[16]Lai CL, Shouval D.Entecavir versus lamivudine for patients withHBeAg-negative chronic hepatitis B[J].NEngl J Med, 2006, 354 (10) ∶1011-1020.

[17]Shouval D, Akarca US, Hatzis G, et al.Continued virologic andbiochemical improvement through 96 weeks of entecavir treatment inHBeAg (-) chronic hepatitis B patients (study ETV-027) [J].Hepatol, 2006, 44 (suppl 2) ∶Abstract 45.

[18]Schiff ER.Entecavir 1.0 mg is consistently superior to lamivudineat 48 weeks across multiple baseline HBV disease characteristics inlamivudine refractory patients[J].Hepatology, 2004, 40 (4 Suppl 1) ∶131.

[19]Yurdaydin C, Sollano J, Hadziyannis S, et al.Entecavir results incontinued virologic and biochemical improvement and HBeAg sero-conversion through 96 weeks of treatment in lamivudine refractoryHBeAg (+) chronic hepatitis B patients (study ETV-026) [J].Hepatol, 2006, 44 (supp1 2) ∶Abstract 80.

[20]姚光弼, 朱玫, 王宇明, 等.恩替卡韦与拉米夫定治疗慢性乙型肝炎随机、双盲、双模拟对照研究[J].中华内科杂志, 2006, 45 (11) ∶891-895.

[21]姚光弼, 任红, 王宝恩, 等.恩替卡韦治疗拉米夫定失效的慢性乙型肝炎一年的疗效[J].中华传染病杂志, 2006, 24 (6) ∶385-389.

[22]Leung N, Peng CY, Hann HW, et al.Entecavir vs.AdefovirHBV DNA Reduction in chronically infected nucleoside-naiveHBeAg (+) adults in a 48-week viral kinetics study[J].Hepa-tol, 2006, 44 (supp1 1) ∶Abstract 982.

[23]Manns MP, Raptopoulou-Gigi M, Sollano J, et a1.Entecaviris well tolerated for the treatment of nucleoside-naive and lamivudi-ne refractory chronic hepatitis B viral infection:PhaseⅡ/Ⅲsafetyresult Abstract 511[Z].Presented at 40th EASL2005.

[24]Colonno R, Rose R.Entecavir resistance is rare in nucleoside na-ive patients with hepatitis B[J].Hepatology, 2006, 44 (6) ∶1656-1665.

施引文献

资源附件(0)

访问统计